TMCnet News
Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic Leukemia Market from 2016 to 2020Technavio has announced the top ten leading vendors in their recent global chronic lymphocytic leukemia (CLL) market 2016-2020 report. The vendors are identified based on their revenue and market dominance in terms of experience, geographical presence, product portfolio, financials, and R&D. Competitive vendor landscape The global CLL therapeutics market is highly competitive with the presence of numerous small and large vendors. The major vendors in the market are AbbVie, F. Hoffmann-La Roche, Gilead Sciences, Johnson & Johnson, Novartis, and Teva Pharmaceuticals. Occasional spurts of competition have also been witnessed from the local manufacturers present in various countries. New players are also entering the market as they foresee huge growth opportunities. Companies such as BioLineRx, Emergent BioSolutions, Infinity Pharmaceuticals, and TG Therapeutics are expected to enter the market during the forecast period. Request for sample report: http://goo.gl/x7keeo "Vendors are also engaged in strategic alliances to market and manufacture drugs. Any company that manufactures and markets drugs that can effectively treat CLL, in addition to exhibiting high safety and efficacy profile, is expected to gain a competitive edge over its competitors," says Barath Palada, a lead oncology analyst from Technavio. Additional Insights: Quarterly Revenue Comparison of Top Vendors (Graph) Key Vendors: F. Hoffmann-La Roche F. Hoffmann-La Roche was established in 1896 and is headquartered in Basel, Switzerland. It is a healthcare company that operates through two business lines: pharmaceuticals and diagnostics. F. Hoffmann-La Roche has an established presence in the global CLL therapeutics market with offerings such as MabThera/Rituxan, Venclexta, and Gazyva. AbbVie AbbVie was incorporated in 2012, and is headquartered in North Chicago, Illinois, US. It is a global biopharmaceutical company that develops and markets advanced therapies that treat diseases such as chronic autoimmune diseases, including psoriasis, rheumatoid arthritis, and Crohn's disease; human immunodeficiency virus; hepatitis C; thyroid disease; endometriosis; and Parkinson's disease. AbbVie has an established presence in the global CLL therapeutics market through Imbruvica. Teva Pharmaceuticals Teva Pharmaceuticals was incorporated in 1944 and is headquartered in Petach Tikva, Israel. The company provides generic medicines and specialty pharmaceutical products. Its products are sold in over 100 countries worldwide, and it has operations in 60 countries. Teva Pharmaceuticals has established its presence in the global CLL therapeutics market. Its key offerings include Treanda and Bendeka. Johnson & Johnson Johnson & Johnson was established in 1887 and is headquartered in New Brunswick, New Jersey, US. The company researches, develops, and sells products across various therapy areas, including immunology, infectious diseases, oncology, neuroscience, and metabolic and cardiovascular diseases. It also develops and sells medical devices and consumer care products. Johnson & Johnson has an established presence in the global CLL therapeutics market. Its key product includes Imbruvica. Gilead Sciences Gilead Sciences was founded in 1987 and is headquartered in Foster City, California, US. It is a biopharmaceutical company that develops and markets medicines for unmet medical needs worldwide. These treatments are primarily targeted at hepatitis B and C, HIV, influenza, and pulmonary diseases. Gilead Sciences has an established presence in the global CLL therapeutics market. Novartis Novartis was founded in 1996 and is headquartered in Basel, Switzerland. It researches, manufactures, and markets healthcare products worldwide. Novartis has an established presence in the global CLL therapeutics market with its key product Arzerra. Other Prominent Vendors: BioLineRx The company discovers, develops, and commercializes compounds for the treatment of various diseases. BioLineRx entry in the global CLL therapeutics market is marked by the development of the drug BL-8040. Emergent BioSolutions The company develops, manufactures, and delivers drugs across various therapy areas and has ventured into the CLL therapeutics market with the drug Otlertuzumab (TRU-016). Infinity Pharmaceuticals The company uses small molecule drug technologies to research and develop cancer drugs and is working on Duvelisib (IPI-145) for the CLL therapeutics market. TG Therapeutics This company acquires, develops, and commercializes pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. It is currently in the process of developing TG-1101 (ublituximab), TG-1101 + ibrutinib for the CLL therapeutics market. Other prominent vendors analyzed in this report are Altor BioScience Corporation, Amgen, Arno Therapeutics, AstraZeneca, Bellicum Pharmaceuticals, Biogen, Boston Biomedical, Celgene Corporation, Genzyme Corporation, iDD biotech, Immunomedics, Innate Pharma SA, Karyopharm Therapeutics, Ligand Pharmaceuticals, MedImmune LLC, Merck Sharp (News - Alert) & Dohme, Molecular Templates, MorphoSys AG, Ono Pharmaceutical, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sunesis Pharmaceuticals, TheraMAB, XEME Biopharma, Xencor, and ZIOPHARM Oncology. Browse Related Reports:
Do you need a report on a market in a specific geographical cluster or country but can't find what you're looking for? Don't worry, Technavio also takes client requests. Please contact [email protected] with your requirements and our analysts will be happy to create a customized report just for you. About Technavio Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies. Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users. If you are interested in more information, please contact our media team at [email protected]. View source version on businesswire.com: http://www.businesswire.com/news/home/20160623005046/en/ |
